Recurrent upper airway collapse during sleep causing apnea, hypoxia, and fragmented sleep.
Also known as: OSA, obstructive sleep apnea, sleep apnea, OSAS, sleep-disordered breathing
Overview
Sleep-related breathing disorder characterized by recurrent episodes of upper airway collapse during sleep with associated reductions in airflow (hypopnea) or complete cessation (apnea), leading to oxyhemoglobin desaturation and sleep fragmentation.
Epidemiology
Estimated to affect ~25% of US adults at any level (AHI >=5) by current criteria, with moderate-severe disease (AHI >=15) in roughly 10-15% (~13% of men, ~6% of women); the majority are undiagnosed. Strong male predominance pre-menopause; gender gap narrows after menopause.
Try two board-style Obstructive Sleep Apnea questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1EndocrineMedium
A 46-year-old man with a BMI of 38 kg/m2 presents to discuss pharmacologic weight management. His partner reports loud snoring with witnessed apneic pauses, and a recent polysomnogram showed an apnea-hypopnea index of 32 events/hour, consistent with moderate-to-severe obstructive sleep apnea. He has no diabetes and takes no medications. He asks specifically about a drug that has an FDA indication for his sleep disorder in addition to weight loss. Which of the following is the most appropriate pharmacologic agent for this patient?
ASemaglutide
BNaltrexone-bupropion
CTirzepatide
DPhentermine
ELiraglutide
Reveal answer & full explanation
Correct answer: C — Tirzepatide
ASemaglutide
BNaltrexone-bupropion
CTirzepatide✓
DPhentermine
ELiraglutide
Why Tirzepatide is correct
Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed for chronic weight management (Zepbound)
The FDA expanded its label to include moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials showing significant reductions in apnea-hypopnea index alongside weight loss
It is the first drug with an FDA indication specifically for OSA, addressing both the metabolic and respiratory components of obesity-related disease
For this non-diabetic patient with a BMI of 38 kg/m2 and an apnea-hypopnea index of 32 events/hour who wants an agent labeled for his sleep disorder, tirzepatide is the only listed drug whose FDA label covers both weight management and OSA
Why the others are wrong
Semaglutide — GLP-1 receptor agonist approved for chronic weight management and cardiovascular risk reduction; it would help him lose weight but carries no FDA indication for OSA, so it does not meet his stated requirement — a buzzword trap assuming all incretin-based drugs share the same labels
Liraglutide — GLP-1 receptor agonist approved for weight loss and type 2 diabetes, with no OSA indication and less weight loss than tirzepatide; same incretin-class confusion
Phentermine — sympathomimetic appetite suppressant indicated only for short-term weight loss, with no OSA indication; a weight-loss buzzword trap that ignores both the chronicity of obesity management and the sleep-disorder requirement
Naltrexone-bupropion — combination of an opioid antagonist and bupropion approved for chronic weight management, so it fits his long-term obesity care, but it carries no FDA indication for OSA and does not meet his stated requirement; same trap of assuming any chronic anti-obesity agent covers obesity-related comorbidities.
Question 2PulmonaryMedium
A 55-year-old man with obesity (BMI 42 kg/m²) and type 2 diabetes mellitus reports daytime somnolence, morning headaches, and witnessed apneas during sleep. Polysomnography shows an apnea-hypopnea index (AHI) of 38 events/hour. Which of the following is the most important cardiopulmonary complication to screen for in this patient?
APulmonary hypertension
BTricuspid regurgitation
CDiastolic dysfunction
DPulmonary thromboembolism
EHypertrophic cardiomyopathy
Reveal answer & full explanation
Correct answer: A — Pulmonary hypertension
APulmonary hypertension✓
BTricuspid regurgitation
CDiastolic dysfunction
DPulmonary thromboembolism
EHypertrophic cardiomyopathy
Why Pulmonary hypertension is correct
An AHI of 38 events/hour defines severe obstructive sleep apnea (OSA; AHI ≥30)
Chronic nocturnal hypoxemia in severe OSA drives hypoxic pulmonary vasoconstriction and Group 3 pulmonary hypertension (PH)
Echocardiography is the appropriate screening study, and CPAP can reduce PH in these patients
PH is a true cardiopulmonary complication that stays clinically silent until advanced, so screening is worthwhile in severe disease
Why the others are wrong
Tricuspid regurgitation — TR is usually a downstream consequence of OSA-related PH rather than the primary entity to screen for, and shows up on the same echo as a sign of elevated right-heart pressures (buzzword-matching 'right heart' without naming the underlying process)
Diastolic dysfunction — OSA is associated with diastolic dysfunction, but it is a left-heart process and not the classic cardiopulmonary complication of severe OSA (premature closure on a real but secondary association)
Hypertrophic cardiomyopathy — HCM is a genetic sarcomeric disorder unrelated to OSA; severe OSA does not cause it (confused-with-X: hypertensive LV hypertrophy is not HCM)
Pulmonary thromboembolism — obesity raises venous thromboembolism risk, which can make PE seem a natural target, but PE is an acute event evaluated when symptoms such as sudden dyspnea or pleuritic pain prompt imaging, not a silent complication screened for in severe OSA; the pulmonary vascular injury here comes from hypoxic vasoconstriction, not clot (confused-with-X: hypoxic vasoconstriction vs thromboembolism)
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Obstructive Sleep Apnea (OSA) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Hypertension (often resistant) — common comorbidity
Atrial fibrillation, polycythemia in severe cases
Differential diagnosis
Central sleep apnea — Absent respiratory effort during apnea (vs OSA which has effort against closed airway); seen in HF, opioids, high altitude, brainstem lesions
Obesity hypoventilation syndrome (Pickwickian) — Daytime hypercapnia (PaCO2 >45) + BMI ≥30 — usually coexists with severe OSA; CPAP first-line when severe OSA coexists (ATS 2019), bilevel NIV (BiPAP/AVAPS) if severe OSA is absent or CPAP fails
Narcolepsy — Excessive daytime sleepiness + cataplexy, sleep paralysis, hypnagogic hallucinations; MSLT with sleep-onset REM
Insomnia — Difficulty initiating/maintaining sleep without breathing-related arousals; normal AHI
Restless legs syndrome / periodic limb movement disorder — Urge to move legs at rest; periodic limb movement index elevated on PSG
Hypothyroidism — Daytime sleepiness, weight gain, cold intolerance; elevated TSH
Diagnostic workup
Diagnostic criteria
AASM 2014: Symptoms (sleepiness, fatigue, snoring/apneas, awakening with gasping, hypertension, mood/cognitive dysfunction) PLUS ≥5 obstructive events/hour on PSG; OR ≥15 events/hour regardless of symptoms.
Labs
TSH if hypothyroidism suspected
CBC (polycythemia in severe hypoxemia)
HbA1c (high diabetes comorbidity); lipid panel
ABG if hypoventilation suspected (PaCO2 >45 → obesity hypoventilation)
Imaging
Imaging not routinely indicated
Cephalometric imaging or upper airway endoscopy for surgical planning
Other studies
Screening: STOP-BANG questionnaire (Snoring, Tiredness, Observed apneas, high blood Pressure, BMI >35, Age >50, Neck circumference >40 cm, male Gender); score 0-2 low, 3-4 intermediate, 5-8 high risk of moderate-severe OSA
Home sleep apnea testing (HSAT) — acceptable for high pretest probability without significant comorbidities; type III device monitoring airflow, effort, oximetry
Severity by Apnea-Hypopnea Index (AHI): mild 5-14, moderate 15-29, severe ≥30 events/hour
Diagnostic algorithm
AHI (events/h)
Severity
Typical Management
<5
Normal
Lifestyle counseling if snoring; reassess if symptoms
5-14
Mild
Lifestyle + CPAP or oral appliance; consider symptom-based
15-29
Moderate
CPAP first-line; oral appliance/hypoglossal stim if intolerant
≥30
Severe
CPAP first-line; aggressively treat comorbidities; consider surgery if refractory
AHI severity stratification and management approach for OSA (AASM 2014).
Treatment
First-line
Behavioral: weight loss (5-10% body weight can substantially reduce AHI), positional therapy (avoid supine sleep), alcohol/sedative avoidance, smoking cessation
Continuous positive airway pressure (CPAP) — first-line and most effective for moderate-severe OSA; acts as a pneumatic splint that holds the collapsible pharynx open throughout the respiratory cycle (does not change central drive or tidal volume); auto-titrating or fixed pressure
BiPAP for CPAP intolerance, very high pressure requirements, or hypoventilation (OHS) without severe OSA or persisting on CPAP
Pharmacotherapy: tirzepatide (SURMOUNT-OSA, FDA-approved 2024 for OSA in obesity) reduces AHI substantially; modafinil/armodafinil (or solriamfetol) for residual sleepiness despite adequate CPAP, only after the device download (adherence, mask leak, residual AHI) is reviewed and treatment-emergent (complex) central apneas, hypoventilation, and insufficient sleep are excluded
Counsel commercial drivers and aviators on regulatory implications; CPAP adherence requirements
STOP-BANG ≥3 is a high-sensitivity screen; ≥5 has high specificity for moderate-severe OSA.
Home sleep apnea testing is acceptable for high pretest probability without significant comorbidity but should NOT be used in HF, COPD, neuromuscular disease, or low pretest probability.
CPAP adherence (>4 h/night on ≥70% of nights) is the metric used by Medicare/insurance for ongoing coverage.
Tirzepatide (SURMOUNT-OSA, 2024) is the first FDA-approved pharmacotherapy for OSA in obesity — substantial AHI reduction.
Obesity hypoventilation syndrome (BMI ≥30 + daytime PaCO2 ≥45) usually coexists with severe OSA; for stable OHS with severe OSA, CPAP is first-line (ATS 2019), while bilevel NIV (BiPAP/AVAPS) is used for OHS without severe OSA, hypoventilation persisting on CPAP, or acute hypercapnic respiratory failure; sustained weight loss is also advised.
References
AASM 2017 — Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea (Kapur et al., J Clin Sleep Med 2017)
AASM 2019 — Treatment of Adult OSA with Positive Airway Pressure — AASM Clinical Practice Guideline (Patil et al., J Clin Sleep Med 2019)
STAR Trial — Upper-Airway Stimulation for Obstructive Sleep Apnea (Strollo et al., NEJM 2014)
SURMOUNT-OSA — Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (Malhotra et al., NEJM 2024)
ATS 2019 — Evaluation and Management of Obesity Hypoventilation Syndrome: An Official American Thoracic Society Clinical Practice Guideline (Mokhlesi et al., Am J Respir Crit Care Med 2019;200(3):e6-e24)
Practice Pulmonary questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.